Literature DB >> 3505236

In vitro screening of iron chelators using models of free radical damage.

G J Kontoghiorghes1, M J Jackson, J Lunec.   

Abstract

The effect of chelators on free radical damage to deoxyribose induced by iron, on IgG by UV irradiation, and on mouse muscle by homogenisation has been studied using the Thiobarbituric acid method and the increase in fluorescence in IgG mixtures. Although there were some variations on the effects of the chelators in the three models, it was shown that most of the chelators could inhibit the noxious effects of the free radicals and some which are orally effective in increasing iron excretion in animals could be potentially useful in preventing iron toxicity in related pathogenic diseases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3505236     DOI: 10.3109/10715768609088062

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  16 in total

1.  Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide.

Authors:  M J Davies; R Donkor; C A Dunster; C A Gee; S Jonas; R L Willson
Journal:  Biochem J       Date:  1987-09-15       Impact factor: 3.857

2.  Herbal extract targets in Leishmania tropica.

Authors:  Bassim I Mohammad; Maani N Al Shammary; Roaa H Abdul Mageed; Nasser Ghaly Yousif
Journal:  J Parasit Dis       Date:  2014-02-16

3.  Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone.

Authors:  Pamela Maher; George J Kontoghiorghes
Journal:  Neurochem Res       Date:  2015-01-06       Impact factor: 3.996

4.  Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone.

Authors:  V A Timoshnikov; T Kobzeva; O Y Selyutina; N E Polyakov; G J Kontoghiorghes
Journal:  J Biol Inorg Chem       Date:  2019-03-13       Impact factor: 3.358

Review 5.  Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.

Authors:  George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

6.  The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; G J Kontoghiorghes; A V Hoffbrand; P Dandona
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Antioxidant Activities of Plumbagin and Its Cu (II) Complex.

Authors:  Mingxiong Tan; Yancheng Liu; Xujian Luo; Zhenfeng Chen; Hong Liang
Journal:  Bioinorg Chem Appl       Date:  2011-10-23       Impact factor: 7.778

Review 10.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.